Indica Labs, Inc.

The rising demand for prostate cancer diagnostics is mainly driven by the growing incidence of the disease, heightened awareness and screening initiatives, and ongoing advancements in diagnostic technologies, projected for the period from 2024 to 2030. LAS VEGAS, Sept. 25, 2024 /PRNewswire/ -- DelveInsight's Prostate Cancer Diagnostics Market Insights report provides the current and forecast market analysis, individual leading prostate cancer diagnostics companies' market shares, challenges, prostate cancer diagnostics market drivers, barriers, trends, and key market prostate cancer diagnostics companies in the market. Key Takeaways from the Prostate Cancer Diagnostics Market Report As per DelveInsight estimates, North America is anticipated to dominate the global prostate cancer diagnostics market during the forecast period. In the test type segment of the prostate cancer diagnostics market, the imaging tests category had a significant revenue share in the prostate cancer diagnostics market in 2023. Notable prostate cancer diagnostics companies such as F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc., Abbott., MDx Health, Siemens Healthcare, OPKO Health, Inc., Genomic Health, Inc., Agilent Technologies, Inc., BD., BIOCEPT, INC., Proteomedix, A3P Biomedical AB, GE HealthCare., Soteria Medical BV, Bio-Techne., Indica Labs, Inc., miR Scientific, MINOMIC®, ACON Laboratories, Inc., Hologic, Inc., and several others, are currently operating in the prostate cancer diagnostics market. In September 2023, MDxHealth announced a research collaboration with the University of Oxford to investigate the correlation between the Genomic Prostate Score (GPS) test and prostate cancer progression following treatment for localized prostate cancer. In July 2023, Quest Diagnostics launched the novel prostate cancer biomarker test through its subspecialty pathology business, AmeriPath, in collaboration with Envision Sciences. Envision Sciences Pty Ltd. is an Australian-based clinical diagnostics company developing a pipeline of biomarker-based cancer diagnostic and prognostic tests in tissue and blood. To read more about the latest highlights related to the prostate cancer diagnostics market, get a snapshot of the key highlights entailed in the Global Prostate Cancer Diagnostics Market Report Prostate Cancer Diagnostics Overview Prostate cancer diagnostics involve a combination of tests and procedures aimed at detecting the presence of cancerous cells in the prostate gland. The initial step typically includes a digital rectal examination (DRE), where a physician physically examines the prostate for abnormalities. However, the most definitive diagnostic tool is the prostate-specific antigen (PSA) blood test, which measures the level of PSA, a protein produced by the prostate. Elevated PSA levels can indicate prostate cancer, though they can also be due to other conditions such as benign prostatic hyperplasia (BPH) or prostatitis. If initial tests suggest the possibility of cancer, further diagnostic procedures are often employed. A prostate biopsy, usually guided by transrectal ultrasound (TRUS), involves taking small tissue samples from the prostate to be examined microscopically for cancer cells. Imaging techniques, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans, can provide detailed views of the prostate and surrounding tissues to assess the extent of the cancer and aid in staging. Together, these diagnostic tools help to accurately identify prostate cancer, determine its aggressiveness, and guide appropriate treatment strategies. Prostate Cancer Diagnostics Market Insights In 2023, North America held the largest share of the prostate cancer diagnostics market compared to other regions. This dominance is largely due to the high incidence of prostate cancer, the growing elderly population, and the region's advanced diagnostic infrastructure. North America's sophisticated healthcare system, featuring cutting-edge hospitals, diagnostic centers, and research facilities, facilitates accurate and timely prostate cancer diagnoses through state-of-the-art imaging technologies like multiparametric MRI (mpMRI) and advanced laboratory testing. Additionally, North America's public health initiatives, advocacy efforts, and healthcare policies bolster prostate cancer awareness and promote regular screening among at-risk individuals. These initiatives, including the Canadian Cancer Society's Prostate Cancer Awareness Month in September, enhance early detection rates and diagnostic testing uptake. As a result, the increasing prevalence of prostate cancer and the region's high-quality healthcare infrastructure, combined with growing government awareness efforts, are expected to significantly drive the prostate cancer diagnostics market in North America throughout the forecast period. To know more about why North America is leading the market growth in the prostate cancer diagnostics market, get a snapshot of the Prostate Cancer Diagnostics Market Outlook Prostate Cancer Diagnostics Market Dynamics The prostate cancer diagnostics market is witnessing significant growth, driven by the i ncreasing prevalence of prostate cancer and advancements in diagnostic technologies. As one of the most common cancers affecting men globally, the need for early and accurate diagnosis has spurred innovation. Traditional diagnostic methods, such as prostate-specific antigen (PSA) testing, have faced criticism for their lack of specificity, leading to false positives and unnecessary biopsies. This has created a demand for more reliable, non-invasive, and precise diagnostic tools, contributing to the expansion of this market. Emerging diagnostic technologies, including liquid biopsies, genomic testing, and advanced imaging techniques, are gaining prominence. Liquid biopsies, for instance, offer a minimally invasive method to detect genetic mutations and monitor disease progression through blood samples. This approach is more patient-friendly and allows for continuous monitoring, unlike traditional biopsies. Genomic testing, on the other hand, enables personalized treatment strategies by identifying specific genetic markers linked to aggressive forms of prostate cancer. These innovations are helping clinicians make more informed decisions, thus improving patient outcomes and driving market growth. The rise of artificial intelligence (AI) and machine learning in medical diagnostics is another key factor influencing the prostate cancer diagnostics market. AI-driven platforms are being developed to enhance the accuracy of imaging technologies such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. These systems can analyze complex data more efficiently, helping radiologists detect early-stage cancer with greater precision. Moreover, AI can assist in interpreting results from genomic and biomarker tests, reducing human error and speeding up diagnosis. The integration of AI in prostate cancer diagnostics is expected to further propel market expansion. However, despite these positive trends, the prostate cancer diagnostics market faces challenges. High costs associated with advanced diagnostic technologies, limited access to healthcare in certain regions, and the potential for overtreatment are key concerns. Nonetheless, ongoing research and development, coupled with growing collaborations between pharmaceutical companies and diagnostic tool developers, are likely to address these challenges and create lucrative opportunities for future growth in the market. Get a sneak peek at the prostate cancer diagnostics market dynamics @ Prostate Cancer Diagnostics Market Dynamics Analysis Prostate Cancer Diagnostics Market Assessment Prostate Cancer Diagnostics Market Segmentation Prostate Cancer Diagnostics Market Segmentation By Test Type: Imaging Tests, Biomarker Tests, Biopsy, Immunohistochemistry, and Others Prostate Cancer Diagnostics Market Segmentation By End User: Hospitals & Clinics, Diagnostic Centers, Research & Academics, and Others Prostate Cancer Diagnostics Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the prostate cancer diagnostics market are set to emerge as the trendsetter explore @ Prostate Cancer Diagnostics Companies Table of Contents Interested in knowing the prostate cancer diagnostics market by 2030? Click to get a snapshot of the Prostate Cancer Diagnostics Market Trends Related Reports Prostate Cancer Market Prostate Cancer Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key prostate cancer companies, including Proteomedix, A3P Biomedical, GE HealthCare, Soteria Medical BV, Bio-Techne, F. Hoffmann-La Roche Ltd., Indica Labs Inc., OPKO HEALTH, INC., miR Scientific, LLC, MINOMIC®, Novartis AG, Johnson and Johnson Services, Inc., Astellas Pharma Inc., Cipla, AstraZeneca, Bayer AG, Zydus Cadila, Pfizer Inc., Avenda Health, The Sanpower Group, among others. Metastatic Prostate Cancer Market Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic prostate cancer companies including AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis among others. Metastatic Castration-Resistant Prostate Cancer Market Metastatic Castration-Resistant Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic castration-resistant prostate cancer companies including AstraZeneca, Merck Sharp & Dohme, Hinova Pharmaceuticals, Pfizer, Astellas Pharma, Janssen Research & Development, Tesaro, Modra Pharmaceuticals, AB Science, Essa Pharma, Eli Lilly and Company, Zr Pharma & GmbH, Bristol-Myers Squibb, Novartis, Ipsen, Exelixis, Takeda, Lantheus Holdings, Kintor Pharmaceutical, MacroGenics, Daiichi Sankyo, Bayer, Arvinas, Novartis, Point Biopharma, Xencor among others. Metastatic Castration-Sensitive Prostate Cancer Market Metastatic Castration-Sensitive Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key mCSPC companies including Myovant Sciences, Pfizer, Bayer, Orion, Novartis, AstraZeneca, Pfizer, Janssen, Merck, Eli Lilly, among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

The 4.0 releases of HALO®, HALO AI, and HALO Link offer researchers and pathologists the latest advances in AI-powered tissue analysis. ALBUQUERQUE, NM / ACCESSWIRE / May 29, 2024 / Indica Labs, the global leader in AI-powered digital pathology solutions, announced today the release of the transformative new version of its industry leading life sciences software. The 4.0 versions of HALO®, HALO AI, and HALO Link offer researchers and pathologists unparalleled ease of use and performance, with even more opportunities to leverage advanced AI-powered image analysis in an open digital pathology ecosystem. The proliferation of artificial intelligence in pathology is powering new insights and workflow efficiencies, and in version 4.0 Indica Labs helps equip users to make tomorrow's discoveries with expanded integration of AI-based tools across the HALO platform. With HALO 4.0, users of Indica Labs' AI-powered image analysis platform can leverage pretrained deep learning-based networks for precise, automated nuclear and membrane segmentation in both brightfield and fluorescence. These advanced networks come ready to deploy, with customization available via HALO AI. Advanced deep learning also underpins the new image registration algorithms in HALO 4.0, powering rapid registration speeds and pinpoint accuracy. Additionally, for users training the next generation of deep learning-based object and tissue classifiers in HALO AI 4.0, the train-by-example toolset includes a new AI-powered annotation tool. This feature, powered by Meta AI's Segment Anything Model and capable of annotating objects as small as a nucleus or as large as a kidney cross section, enables precise annotations with just a click, greatly streamlining the construction of training sets. "Since Indica's founding 13 years ago, countless user input and technical developments have brought us to the release of version 4.0 of our life sciences products," said Dr. Anne Hellebust, Director of Product for Life Sciences. "We're proud to continue our leadership in the digital pathology industry, and we look forward to seeing how users will leverage the advanced AI-powered toolset provided in the latest release." To help users meet the challenges of modern tissue analysis, version 4.0 builds on Indica Labs' legacy of powerful, intuitive software, setting new standards in slide viewing and workflow optimization. At the heart of HALO 4.0 is a new GPU-accelerated viewer that provides a seamless experience across all supported with smooth panning and zooming of highly multiplexed and extensively annotated images. Users of HALO Link 4.0, Indica Labs' platform for collaborative pathology, will also experience a major performance boost and more time for review and analysis thanks to an updated image server. The new server also enables viewing of HALO interactive markups for richer data visualization, and these markups are now available across even more modules in 4.0, including those designed for in situ hybridization and RNAscope™. Workflows have been optimized throughout the 4.0 releases, with HALO offering customizable analysis outputs so users can limit results to suit the application and even create calculations using existing outputs. Additionally, the integration between HALO and HALO Link is now even deeper, with slide metadata from HALO Link able to be viewed, sorted, and filtered in HALO 4.0, informing workflows and enriching data analysis. Lastly, new features and functionalities have been introduced throughout the classifier workflow, with new classifier pipeline capability, queueing of training jobs, and a colorblind-friendly default pallet. In version 4.0, Indica Labs is introducing its first add-on for HALO Link, providing users powerful features intended to complement existing processes to aid Good Laboratory Practices within the research pathology space. The Compliance Add-on provides system-level auditing that captures all data-generating or -altering activity, which can then be sorted and filtered for users, actions, or by date, and exported as a spreadsheet. The Add-on also includes a reason for change workflow, configurable separately from the auditing feature, that captures users' reasons for change and records them within the audit log. Reach out to info@indicalab.com to discuss how the 4.0 releases can advance your tissue analysis projects with one of our Field Applications Scientists. About Indica Labs Indica Labs is the global leader in AI-powered digital pathology software and services. Our flagship HALO® and HALO AI platform revolutionizes quantitative evaluation of whole slide images. HALO Link provides collaborative image management while HALO AP® and HALO AP Dx deliver enterprise digital pathology for primary diagnosis with regulatory clearances in multiple markets. Through a commitment to open pathology, performance, scalability, and ease-of-use, we help pharma companies, diagnostic labs, hospitals, research organizations, and Indica's own Cloud and Pharma Services make discoveries and diagnoses that transform patient care and scientific discovery. Indica Labs Media Contact: Dr. Kate Lillard Tunstall kate@indicalab.com SOURCE: Indica Labs View the original press release on accesswire.com

BRIDGEWATER, N.J., May 22, 2024 /PRNewswire/ -- Indica Labs, an industry leader in AI-powered digital pathology solutions, and Hamamatsu Photonics K.K., a pioneer in whole slide imaging systems, announce that the U.S. Food and Drug Administration (FDA) has issued a 510(k) clearance to Indica Labs for HALO AP Dx, an enterprise digital pathology platform. HALO AP Dx is indicated for primary diagnosis of surgical pathology slides prepared from formalin-fixed paraffin embedded (FFPE) tissue scanned by the NanoZoomer® S360MD Slide scanner1. This 510(k) clearance from the FDA expands on an established partnership between Indica Labs and Hamamatsu Photonics K.K. Steven Hashagen, founder and CEO of Indica Labs said, "This FDA clearance for primary diagnosis of surgical pathology slides prepared from FFPE tissue is a significant milestone for HALO AP Dx that builds upon our prior CE-IVDR certification for HALO AP®. We're proud that our collaboration with Hamamatsu allowed us to leverage images from their NanoZoomer Slide scanner and led directly to this landmark achievement that will provide value to patients and healthcare providers alike." HALO AP® is a case-centric digital pathology platform that is deployed worldwide and has transformed the way pathologists and researchers analyze, manage, and utilize digital pathology images through its comprehensive suite of tools and features for efficient and accurate image evaluation, management, and collaboration. HALO AP® and Hamamatsu NanoZoomer Slide scanners are already in use together at a variety of institutions and centers in the US for research purposes, and in the EU and the UK for clinical applications. In the US, Indica Labs will continue to offer HALO AP® for Research Use Only applications, and will now also offer HALO AP Dx for primary diagnosis of surgical pathology slides prepared from FFPE tissue. The NanoZoomer® S360MD Slide scanner system is an expertly crafted digital pathology solution that displays images and provides image management tools and aids qualified pathologists in the review and interpretation of digital images of surgical pathology slides prepared from FFPE tissue. Fumio Iwase, Executive Officer, Division Director, Systems Division at Hamamatsu Photonics K.K. said, "We believe that comprehensive tools are key to the advancement of digital pathology. The 510(k) clearance of the Indica Labs HALO AP Dx for review of images acquired with the previously 510(k)-cleared NanoZoomer® S360MD Slide scanner system is a testament to the unwavering quality and confidence that both partners consistently deliver to our valued customers. This regulatory achievement represents a significant stride forward, underscoring our joint commitment to providing cutting-edge solutions that elevate standards in the digital pathology field and empower professionals in their diagnostic endeavors." 1HALO AP Dx (K232833) is FDA-cleared for primary diagnostic use with the Hamamatsu NanoZoomer® S360MD Slide scanner in the US. In addition, HALO AP Dx provides built-in compliance and certifications with FDA 21 CFR Part 11 and HIPAA. HALO AP® is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland. HALO AP is For Research Use Only in the US and is not FDA cleared for clinical diagnostic use. In addition, HALO AP provides built-in compliance and certifications with FDA 21 CFR Part 11, HIPAA, and GDPR. About Indica Labs Indica Labs is the world's leading provider of AI-powered digital pathology software and services. Our flagship HALO® and HALO AI platform powers quantitative evaluation of digital pathology images. HALO Link facilitates research-focused image management and collaboration while HALO AP® and HALO AP Dx deliver enterprise digital pathology for primary diagnosis with regulatory clearances in multiple markets. Through a commitment to open pathology and a combination of performance, scalability, and usability, our software solutions enable pharma companies, diagnostic labs, hospitals, research organizations, and Indica's own contract Pharma Services team to advance tissue-based research, clinical trials, and diagnostics. About Hamamatsu Corporation Hamamatsu Corporation is the North American subsidiary of Hamamatsu Photonics K.K. (Japan), a leading manufacturer of devices for the generation and measurement of infrared, visible, and ultraviolet light. These devices include photodiodes, silicon photomultipliers, photomultiplier tubes, scientific light sources, infrared detectors, image sensors, spectrometers, and cameras. The parent company is dedicated to the advancement of photonics through extensive research. This corporate philosophy results in state-of-the-art products which are used throughout the world in scientific, industrial, and commercial applications. Information furnished by Hamamatsu Corporation is believed to be reliable. However, no responsibility is assumed for possible inaccuracies or omissions. Specifications are subject to change without notice.